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Aim. To analyse the association of MGP gene promotor T-138C polymorphism (rs1800802) with known risk fac- 
tors of atherosclerosis and its complications (hypercholesterolemia, hypertension, high body mass index, diabe-
tes, smoking, hypercoagulability) in patients with ischemic stroke (IS) of atherothrombotic origin. Methods. Ve-
nous blood of 170 IS patients  was used for genotyping. The MGP gene polymorphism was examined by PCR-
RFLP methodology. Results. The carriers of a minor allele (T/C + C/C) had higher total cholesterol (5.4 ± 0.19
vs 4.8 ± 0.15 mmol/l, P = 0.025) and LDL-cholesterol concentrations (3.6 ± 0.17 vs 3.0 ± 0.14 mmol/l, P =
= 0.008), and lower HDL-cholesterol level (0.96 ± 0,04 vs 1.1 ± 0.03 mmol/l, P = 0.029) in blood plasma than 
the  major allele homozygotes (T/T). Conclusions. It has been found no association  between T-138C polymor-
phism of MGP gene and known risk factors for atherosclerosis and its complications (BMI, hypertension, diabe-
tes, smoking, hypercoagulability) in patients with IS from the northeastern region of Ukraine. IS patients with
the minor allele have more pronounced atherogenic changes in blood plasma lipoproteins as compared with the
major allele homozygotes.
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Introduction. Matrix gamma-carboxyglutamic acid
protein (MGP) is a mineral-binding extracellular pro-
tein synthesized in the vascular tissue. It belongs to a fa-
mily of proteins that contain glutamyl residues, post-
translationally modified by vitamin K-dependent gam-
ma-glutamyl carboxylase into gamma-carboxygluta-
mic acid (Gla) residues [1].
MGP is known to be one of the most potent natural
inhibitors of ectopic mineralization. The homozygous
MGP deficient mice were observed to die within 8 weeks 
as a result of arterial calcification that led to blood ves-
sel rupture [2]. MGP is highly expressed on calcified
atherosclerotic plaques in humans [3], and it can modi-
fy calcification in such plaques and the risk of cardio-
vascular disease [4–6]. It is thought that anticalcifying
activity of MGP depends on Gla-residues, which are
able to bind calcium [7]. 
The human MGP gene located on the chromosome
12p13.1-p12.3 consists of 4 exons [8]. Numerous sing-
le nucleotide polymorphisms (SNPs) were identified in 
both the coding and regulatory regions of MGP gene.
Among those, the T-138C polymorphism of gene pro-
moter was under consideration in a number of studies
[9–15]. In vitro investigations suggest that T-138C
polymorphism in MGP is associated with altered pro-
motor activity [11, 13, 14]. In addition, there is some
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evidence that this variant of SNP is related to the level
of serum MGP, arterial calcification, and coronary ar-
tery disease [9–11, 13], although these data are not con- 
sistent [14, 15].
Ischemic stroke (IS) is, in many instances, the con-
sequence of a thrombus forming on a ruptured athero-
sclerotic plaque. Abnormal calcium salts content  in the 
arterial vessels is considered to be a novel marker of
atherosclerosis and related to cerebrovascular disease
[16].
Considering the central role of MGP in vascular cal-
cification and similar pathogenesis of the coronary arte-
ry disease and severe cerebrovascular events, we hypo- 
thesized that the T-138C polymorphism in MGP gene
promoter might influence the risk of IS.
In our previous studies no association has been found
between the T-138C polymorphism of MGP gene and
IS in the representatives of the northern region of Uk-
raine [17].
The   purpose of the present study was to analyse
the association of the MGP gene promotor polymor-
phism with well the established risk factors of athero-
sclerosis and its complications such as hypercholestero-
lemia, hypertension, high body mass index, diabetes,
smoking, and hypercoagulability in the patients with IS 
of atherothrombotic origin.
Materials and methods. Study subjects. Studied a
group included 170 unrelated Ukrainian patients with a
mean  age  of 64.8 ± 9.5 years who had IS and had been
under medical surveillance and outpatient treatment in
the 5th Sumy Clinical Hospital since 2009 to 2011. A fi-
nal diagnosis of IS was established on the basis of cli-
nical, computed tomography and magnetic resonance
imaging investigations. Each case of IS was assessed ac-
cording to the TOAST criteria [18]. The patients with
IS of cardioembolic origin and undetermined etiology
were excluded from the studied group. The clinical signs 
included generally accepted parameters related to the
risk factors for atherosclerosis and atherothrombotic IS:
body mass index (BMI), blood pressure (BP), the con-
tent of lipids and lipoproteins in blood plasma, and
some indices of blood coagulation (prothrombin time).
According to these parameters all patients were divided 
into the pairs of subgroups defined by (1) BMI ( < 27 or 
≥ 27 kg/m2), (2) BP (non-hypertensive or hypertensive: 
systolic BP > 140 mmHg, diastolic BP > 90 mmHg),
(3) low density lipoprotein cholesterol (LDL-C) con-
centration ( ≤ 3.5 or > 3.5 mmol/l), (4) diabetes mellitus 
type 2 (non-diabetic or diabetic), (5) smoking (non-
smoking or smoking), and (6) prothrombin time ( ≥ 9 or 
< 9 '').
The study had been previously approved by the
Ethic Committee on Medical Research of the Medical
Institute of Sumy State University. An appropriate in-
formed consent was obtained from all patients. Blood
sampling for genotyping was performed under sterile
conditions into 2.7 ml S-Monovette («Sarstedt», Ger-
many) containing EDTA potassium salt as an anticoa-
gulant, the samples were frozen and stored at –20 oC. 
Amplification and genotyping. DNA for genoty-
ping was extracted from venous blood using commer-
cially available kits («Isogene Lab Ltd», Russian Fede- 
ration) according to the manufacturer’s protocol. To
identify the MGP promotor T-138C polymorphism (rs
1800802) PCR with subsequent restriction fragment
length polymorphism (RFLP) analysis was performed.
Specific region of the MGP gene was amplified using a
pair of specific primers: upstream (sense) – 5'-AAGC
ATACGAAGGCCAAAACTTCTGCA-3' and down-
stream (antisense) – 5'-GAACTAGCATTGGAACTT
TTCCCAACC-3'. Primers were provided by Metabion
(Germany). PCR was performed for 33 cycles in a 25 µl 
volume containing 50–100 ng of DNA, 5 µl 5 × PCR-
buffer, 1.5 mM magnesium sulfate, 200 µM of each
dNTP, 20 pM of each primer and 0.5 U of Taq DNA po- 
lymerase («Fermentas», Lithuania). PCR was carried
out in a termocycler GeneAmp PCR System 2700 («Ap- 
plied Biosystems», USA). Six microlitres (6 µl) of the
PCR products (142 bp) were subjected to digestion
with 3 U BseNI («Fermentas») and incubated at 37 oC
for 18 h. The presence of thymine at position –138 of
the promoter prevented the restriction and  in the case of
substitution for cytosine BseNI  cleaved the amplified
fragment of the promoter into two fragments 118 bp
and 24 bp in length. The restriction fragments were se-
parated by electrophoresis and analysed on the ethidi-
um bromide-stained 2.5 % agarose gel using ultraviolet 
transillumination.
Statistical analysis. The normal distribution and ho-
mogeneity of variances were  tested before further sta-
tistical analyses. The χ2-test was used to assess the de-
viations from the Hardy-Weinberg equilibrium for ge-
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notype frequencies, and it was also used for compa-
rison of the allele and genotype frequencies between
different studied subgroups. Since there were few indi-
viduals with the CC genotype, we tested whether the
variable means differed significantly between the sub-
jects with and without the C variant (TC + CC vs TT).
The comparison of variables between the groups of ge-
notypes was performed using ANOVA or two-tailed
Student’s t-test. The differences were considered stati-
stically significant with a P-value < 0.05. All statistical
analyses were performed using the Statistical Package
for Social Science program (SPSS for Windows, version 
17.0, SPSS Inc., Chicago, IL). 
Results and discussion.  The known IS risk factors 
include increased BMI, hypertension, elevated levels
of cholesterol and LDL in blood plasma, diabetes mel-
litus, hypercoagulability, and smoking, i. e. factors rela-
ting to atherogenesis and thrombi formation. In Table 1 
some clinical characteristics manifesting the above-
mentioned IS risk factors inherent to the patients divi-
ded into two subgroups according to their genotype
(T/T and T/C + C/C). The statistically significant diffe-
rences are revealed between these two subgroups only
for cholesterol levels. The carriers of   minor allele (T/C +
+ C/C) had higher total cholesterol (5.4 ± 0.19 vs 4.8 ±
± 0.15 mmol/l, P = 0.025) and LDL-cholesterol con-
centrations (3.6 ± 0.17 vs 3.0 ± 0.14 mmol/l, P = 0.008), 
and lower HDL-cholesterol level (0.96 ± 0,04 vs 1.1 ±
± 0.03 mmol/l, P = 0.029) than  the  major allele homo-
zygotes (T/T). 
The division of patients into subgroups according
to the presence or absence of known stroke risk factors
allowed   a comparative analysis of the partition of their 
genotypes. As shown in Table 2, statistically significant
differences were not established for any comparison.
Arterial wall calcification is a common pathologi-
cal process that is of significance by itself (Moncke-
berg’s sclerosis) and can complicate the development
of atherosclerotic plaques  contributing to their instabili- 
ty. Therefore, investigation of the factors related to the
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Parameter T/T T/C + C/C Total P
n 104 66 170 –
Age, years 65.5 ± 0.9 63.3 ± 1.2 64.7 ± 0.7 0.141
Gender, M/F 58/46 40/26 98/72 0.534
BMI (M), kg/m2 27.8 ± 0.6 27.4 ± 0.6 27.6 ± 0.4 0.703
BMI (F), kg/m2 29.0 ± 0.7 28.9 ± 0.7 29.0 ± 0.5 0.943
Systolic BP, mmHg 168.0 ± 2.9 165.4 ± 3.5 167.0 ± 2.2 0.573
Diastolic BP, mmHg 96.3 ± 1.7 93.9 ± 1.6 95.4 ± 1.2 0.348
Total cholesterol*, mmol/l 4.8 ± 0.15 5.4 ± 0.19 5.0 ± 0.12 0.025
HDL-cholesterol*, mmol/l 1.1 ± 0.03 0.96 ± 0.04 1.0 ± 0.02 0.029
LDL-cholesterol*, mmol/l 3.0 ± 0.14 3.6 ± 0.17 3.3 ± 0.11 0.008
Triglyceride*, mmol/l 1.7 ± 0.08 1.8 ± 0.1 1.7 ± 0.06 0.523
Prothrombin time, s 9.6 ± 0.2 9.3 ± 0.24 9.5 ± 0.2 0.320
Fasting glucose, mmol/l 5.9 ± 0.15 6.0 ± 0.19 5.9 ± 0.12 0.792
Diabetes, (%) 18 (17.3) 12 (18.2) 30 (17.6) 0.884
Smoking, (%) 32 (30.8) 18 (27.3) 50 (29.4) 0.626
N o t e. Data are mean ± SE; n – number of subjects; HDL – high density lipoprotein; LDL – low density lipoprotein; *n = 96 for T/T genotype and
n = 61 for T/C + C/C genotypes. 
Table 1
Clinical characteristics of ischemic stroke patients with different MGP gene T-138C genotype
mechanisms of vascular calcification is of increased in- 
terest, as evidenced by a number of literature sources
[5, 19–21]. 
MGP is well known to play a pivotal role in preven- 
ting the blood vessels mineralization. An exact mecha-
nisms by which MGP inhibits the ectopic soft tissues
calcification  are not yet clear. The data on relationship
between MGP and the calcifying vascular lesions are
contradictory. Thus, Braam et al. [22] showed that the
development of severe atherosclerosis was accompanied 
by an increase in the serum MGP concentration. In cont-
rast, Jono et al. [23] found that the serum MGP levels
inversely correlated with the coronary artery calcifica-
tion. Finally, O’Donell et al. [24], showing the relation-
ship between the level of MGP and a number of risk fac-
tors, found no correlation between the serum MGP con- 
centration and calcification of the coronary arteries.
With regard to the association between MGP gene
polymorphisms and (a) the serum levels of the protein,
(b) arterial calcification, and (c) the severe consequen-
ces of atherosclerosis, this problem has not been investi-
gated (as for the brain vessels and ischemic stroke) or
has been limited to the studies on the coronary arteries
and coronary artery disease complications (acute coro-
nary syndrome, myocardial infarction). It should be
mentioned that the results of these few   studies  are  not
consistent. 
Thus, Farzaneh et al. [11] found the statistically sig-
nificant association between the MGP promoter T-
138C polymorphism and serum MGP concentration in
the healthy individuals from Netherlands. In contrast to 
this, Crosier et al. [10] could not find any relation bet-
ween T-138C polymorphism and the levels of MGP in
the blood serum of healthy older males and females of
European descent from Massachusetts (USA). In the sa-
me study, the association of two other MGP polymor-
phisms (G-7A and Thr83Ala) with the serum MGP con-
centration was shown. Various methods of analysis re-
vealed that in males, homozygous carriers of the minor
allele, the T-138C polymorphism of the MGP gene was 
associated with a decreased level of coronary artery cal-
cification, relative to the major allele carriers [10]. Such
association was not found in females.
In the Coronary Artery Risk Development in Young
Adults (CARDIA) study, the population-based investi- 
gation of cardiovascular disease in young African-Ame- 
50
GARBUZOVA V. Yu. ET AL. 
Genotype
BMI, n (%) Arterial pressure, n (%)
< 27 ≥ 27 Normal Elevated
T/T 48 (60.7) 56 (61.5) 25 (59.5) 79 (61.7)
T/C 24 (30.4) 29 (31.9) 13 (31.0) 40 (31.3)
C/C 7 (8.9) 6 (6.6) 4 (9.5) 9 (7.0)
In total, n 79 91 42 128
P 0.852 0.852 0.868
Genotype
Diabetes, n (%) Smoking, n (%)
Non-diabetic Diabetic Non-smoking Smoking
T/T 86 (61.4) 18 (60.0) 72 (60.0) 32 (64.0)
T/C 44 (31.4) 9 (30.0) 38 (31.7) 15 (30.0)
C/C 10 (7.1) 3 (10.0) 10 (8.3) 3 (6.0)
In total, n 140 30 120 50
P 0.866 0.829
N o t e. n – number of subjects; BMI – body mass index; LDL-C – low density lipoprotein cholesterol; PT – prothrombin time; *13 patients
without data on this index were excluded from calculation.
Table 2
Distribution of genotypes by the T-138C polymorphism of the MGP gene in subgroups of IS patients with regards to different disease risk
factors (%)
rican and non-Hispanic white participants, the T-138C
polymorphism of the MGP gene was analysed regar-
ding the association with the presence or absence of co- 
ronary artery calcification [13]. This SNP was also stu-
died in autopsy samples for an association with several
measures of atherosclerotic calcification [14]. However,
no connection between the T-138C polymorphism and
vascular calcification was found in either of these studies. 
Italian scientists defined the distribution of MGP
promoter T-138C polymorphism in patients with chro-
nic kidney disease (CKD) and age- and sex marched
healthy controls [9]. It was shown that the frequency of
the major T allele was significantly higher in the CKD
group versus controls. T/T homozygotes were associa-
ted with cardiovascular events in CKD patients. It was
concluded that some MGP gene polymorphisms might
be a negative prognostic factor for the progression of
CKD and for severe cardiovascular disorders.
It should be noted that the majority of studies cited
here  were devoted to the relation of MGP to coronary
artery calcification and myocardial infarction. As to ce- 
rebral artery atherosclerosis and its severe events such
as IS, the role of arterial calcification in this disease and 
the association of MGP with cerebrovascular patholo-
gies were the subject of investigation and discussion
only in a few publications. In particular, Bos et al. [16]
established a close relationship between calcification
in the various vessel beds outside the brain and imaging 
markers of vascular brain disease. Calcification in each
vessel bed was shown to be associated with the presen-
ce of cerebral infarcts and with a larger volume of white 
matter lesions (WMLs). The most prominent associa-
tions were found between the intracranial carotid calci-
fication and WML volume and between the extracra-
nial carotid calcification and infarcts. 
Acar et al. [25] studied a relation  of serum MGP le- 
vels to the development of intracerebral hemorrhages
(ICH) and found that in patients with ICH, the serum
MGP concentration was much lower than in control
group. Moreover, in the non-survivors, the serum MGP 
levels were significantly lower in comparison to the sur-
vivors. According to the authors, measurement of this
parameter may be of value to estimate mortality. 
At present, there are only a few publications concer-
ning relation of the MGP SNPs to cerebrovascular di-
sease. Del Rio-Espinola et al. [26] tried to find genetic
predictors of reocclusion after successful fibrinolytic
therapy during the acute phase of IS. Analysing 236 po- 
lymorphisms, they revealed an association between the
MGP G-7A polymorphism and reocclusion risk. Accor-
ding to the authors, the predictive scale that was gene-
rated permits the stratification of patients by their re-
occlusion risk with a higher accuracy than clinical para-
meters only. 
In our previous study, we have defined the distribu- 
tion of genotypes for the MGP promoter T-138C poly-
morphism in IS and control patients from the northea-
stern region of Ukraine [17]. We have not found any as- 
sociation between this SNP and stroke. The distribu-
tion of T/T, T/C and C/C genotypes in patients with IS
was 61.2, 31.2 and 7.6 % respectively. The correspon-
ding distributions in the control group were 59.7, 35.6,
4.8 % (P = 0.521 by the χ2 test). Almost the same results 
were obtained when all patients were divided by gender.
As shown in this paper, no correlation has also been 
found between the T-138C genotypes and IS risk in the
subgroups of IS patients formed according to the pre-
sence or absence of known risk factors of atherosclero-
sis (BMI, hypertension, hypercholesterolemia, diabe-
tes, smoking, hypercoagulability). Only with regards to 
the plasma lipoproteins cholesterol concentrations, the
statistically significant differences were revealed bet-
ween the carriers of different allelic variants of the MGP
gene. In IS patients who are the carriers of a minor
allele -138C (genotypes T/C and C/C), the levels of
total cholesterol and LDL-cholesterol were higher and
the concentration of HDL-cholesterol was lower than
in the persons with T/T genotype. It could mean that the 
presence of the  -138C allele predisposes to more pro-
nounced atherogenic changes in the blood plasma lipo-
proteins. Atherosclerotic plaques and thrombi are able to 
cause atherothrombotic ischemic stroke, one of the most
common pathogenetic variants of  stroke. 
The influence of T-138C polymorphism on various
pathological processes can be realized through the chan- 
ges in the MGP promoter activity. In [13], an analysis
of the MGP promoter activity revealed that the -138C
allele reduced the promoter activity by 20 % in the rat
vascular smooth muscle cells (VSMC) and by up to
50 % in the human fibroblast cell line. Moreover, it was 
demonstrated that a nuclear protein was specifically
bound in the region covering the T-138C polymorphic
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site, and that the binding was enhanced in the presence
of the T allele. Thus, the difference in the promoter acti-
vity might be explained by differential binding of a nuc-
lear protein that is important in MGP transcription.
In another study [11], the influence of T-138C poly-
morphism on gene expression was examined using the
reporter gene constructs transiently transfected into
VSMCs. It was demonstrated that this SNP impacted the
transcriptional activity of the MPG gene. The activity
of  -138C variant of promoter was 4 times higher than
that of the -138T variant. On the other hand, it was
shown that the -138T allelic variant bound AP-1 comp- 
lexes and was induced by the phorbol 12-myristate
13-acetate treatment, while the -138C variant was re-
sistant to the compound, confirming that AP-1 factors 
preferentially are bound to the -138T variant. It was
suggested that the -138C variant provided protection
against tissue calcification in VSMC due to higher le-
vels of the MGP transcription. Equally, the responsive-
ness of the -138T site to extracellular stimuli mediated
via AP-1 may result in altered susceptibility to calcifica- 
tion. Clearly, these results are  inconsistent with the abo-
ve-mentioned findings [13].
Conclusions. No association has been found bet-
ween the T-138C polymorphism of  MPG gene and
known risk factors for atherosclerosis and its complica- 
tions (BMI, hypertension, diabetes, smoking, hypercoa-
gulability) in the patients with IS from the northeastern
region of Ukraine. However, in the carriers of the mi-
nor allele (genotypes T/C and C/C) the levels of total
cholesterol and LDL-cholesterol were higher and the
concentration of HDL-cholesterol was lower than in
the persons with the T/T genotype. It means that the IS
patients with the minor allele have more pronounced
atherogenic changes in the blood plasma lipoproteins
as compared with the major allele homozygotes. 
Ïîë³ìîðô³çì T-138C ãåíà MGP àñîö³éî âà íèé ç ð³âíÿ ìè 
õî ëåñ òå ðî ëó ïëàç ìè êðîâ³ ³ íå ïî â’ÿ çà íèé ç ³íøè ìè ôàê òî ðà ìè 
ðè çè êó àòå ðîñ êëå ðî çó ó ïàö³ºíò³â ç ³øåì³÷íèì ³íñóëü òîì
Â. Þ. Ãàð áó çî âà, Î. Â. Ïî ëîí³êîâ, Þ. Î. Àòàìàí, Ò. ². Ìè õàé ëî âà,
Î. À. Îáó õî âà, Î. ². Ìàò ëàé, Î. Â. Àòàìàí
Ðå çþ ìå
Ìåòà. Ïðî à íàë³çó âà òè çâ’ÿ çîê ïîë³ìîðô³çìó T-138C ïðî ìî òî ðó
ãåíà MGP (rs1800802) ç â³äî ìè ìè ôàê òî ðà ìè ðè çè êó àòå ðîñ êëå -
ðî çó òà éîãî óñêëàä íåíü (ã³ïåð õî ëåñ òå ðî ëåì³ÿ, ã³ïåð òåíç³ÿ, âè ñî -
êèé ïî êàç íèê ³íäåê ñó ìàñè ò³ëà, öóê ðî âèé ä³àáåò, êóð³ííÿ, ï³äâè-
ùåíà êî à ãó ëÿö³éíà çäàòí³ñòü êðîâ³) ó ïàö³ºíò³â ç ³øåì³÷íèì ³í-
ñóëü òîì àòå ðîò ðîì áî òè÷ íî ãî ïî õîä æåí íÿ. Ìå òî äè. Äëÿ ãå íî -
òè ïó âàí íÿ âè êî ðèñ òà íî âå íîç íó êðîâ 170 õâî ðèõ íà ³øåì³÷íèé ³í-
ñóëüò. Ïîë³ìîðô³çì ãåíà MGP âèç íà ÷å íî ìå òî äîì ïîë³ìå ðàç íî¿
ëàí öþ ãî âî¿ ðå àêö³¿ ç íà ñòóï íèì àíàë³çîì äîâ æè íè ðåñ òðèêö³éíèõ 
ôðàã ìåíò³â ïðè âè ÿâ ëåíí³ ¿õ åëåê òðî ôî ðå çîì â àãà ðîç íî ìó ãåë³.
Ðå çóëü òà òè. Íîñ³¿ ì³íîð íî ãî àëå ëÿ (T/C + C/C) ìàëè âèù³ ïî êàç -
íè êè çà ãàëü íî ãî õî ëåñ òå ðî ëó (5,4 ± 0,19 ïðî òè 4,8 ± 0,15 ììîëü/ë,
P = 0,025) ³ õî ëåñ òå ðî ëó ë³ïî ïðî òå¿í³â íèç ü êî¿ ãóñòèíè (3,6 ± 0,17
ïðî òè 3,0 ± 0,14 ììîëü/ë, P = 0,008), à òà êîæ íèæ÷èé ð³âåíü õî -
ëåñòåðî ëó ë³ïî ïðî òå¿í³â âè ñî êî¿ ãóñ òè íè ó ïëàçì³ êðîâ³, í³æ ãîìî-
çè ãî òè çà îñíîâ íèì àëå ëåì (T/T). Âèñ íîâ êè. Íå çíàé äå íî çâ’ÿç êó
ì³æ ïîë³ìîðô³çìîì T-138C ãåíà MGP ³ â³äî ìè ìè ôàê òî ðà ìè ðè-
çèêó àòå ðîñ êëå ðî çó òà éîãî óñêëàä íåíü (³íäåê ñîì ìàñè ò³ëà, ã³ïåð-
òåíç³ºþ, öóê ðî âèì ä³àáå òîì, êóð³ííÿì, ï³äâè ùå íîþ êî à ãó ëÿö³é-
íîþ çäàòí³ñòþ êðîâ³) ó õâî ðèõ íà ³øåì³÷íèé ³íñóëüò ç ï³âí³÷íî-
ñõ³äíî ãî ðåã³îíó Óêðà¿ íè. Ó ïàö³ºíò³â – íîñ³¿â ì³íîð íî ãî àëå ëÿ – çà-
ðåºñòðî âà íî âè ðà æåí³ø³ çì³íè ë³ïî ïðî òå¿í³â ïëàç ìè êðîâ³ àòå ðî-
ãåí íî ãî õà ðàê òå ðó ïîð³âíÿ íî ç ãî ìî çè ãî òà ìè çà îñíîâ íèì àëå ëåì.
Êëþ ÷îâ³ ñëî âà: êàëü öèô³êàö³ÿ àð òåð³é, ³øåì³÷íèé ³íñóëüò,
ìàò ðèê ñíèé á³ëîê Gla, ïîë³ìîðô³çì ïî îäè íî êèõ íóê ëå î òèä³â.
Ïî ëè ìîð ôèçì T-138Ñ ãåíà MGP àñ ñî öè è ðî âàí ñ óðîâ íÿ ìè 
õî ëåñ òå ðî ëà ïëàç ìû êðî âè è íå ñâÿ çàí ñ äðó ãè ìè ôàê òî ðà ìè 
ðèñ êà àòå ðîñ êëå ðî çà ó ïà öè åí òîâ ñ èøå ìè ÷åñ êèì èí ñóëü òîì
Â. Þ. Ãàð áó çî âà, À. Â. Ïî ëî íè êîâ, Þ. À. Àòàìàí, 
Ò. È. Ìè õàé ëî âà, Î. À. Îáó õî âà, Î. È. Ìàò ëàé, À. Â. Àòàìàí
Ðå çþ ìå
Öåëü. Ïðî à íà ëè çè ðî âàòü ñâÿçü ïî ëè ìîð ôèç ìà T-138C ïðî ìî òî -
ðà ãåíà MGP (rs1800802) ñ èç âåñ òíû ìè ôàê òî ðà ìè ðèñ êà àòå -
ðîñ êëå ðî çà è åãî îñëîæ íå íèé (ãè ïåð õî ëåñ òå ðî ëå ìèÿ, ãè ïåð òåí-
çèÿ, âû ñî êèé ïî êà çà òåëü èí äåê ñà ìàñ ñû òåëà, ñà õàð íûé äè à áåò,
êó ðå íèå, ïî âû øåí íàÿ êî à ãó ëÿ öè îí íàÿ ñïî ñîá íîñòü êðî âè) ó ïà öè -
åí òîâ ñ èøå ìè ÷åñ êèì èí ñóëü òîì àòå ðîò ðîì áî òè ÷åñ êî ãî ïðî èñ -
õîæ äå íèÿ. Ìå òî äû. Äëÿ ãå íî òè ïè ðî âà íèÿ èñ ïîëü çî âà ëè âå íîç-
íóþ êðîâü 170 áîëü íûõ èøå ìè ÷åñ êèì èí ñóëü òîì. Ïî ëè ìîð ôèçì ãå-
íà MGP îïðå äå ëÿ ëè ìå òî äîì ïî ëè ìå ðàç íîé öåï íîé ðå àê öèè ñ ïî -
ñëå äó þ ùèì àíà ëè çîì äëè íû ðåñ òðèê öè îí íûõ ôðàã ìåí òîâ ïðè èõ
âû ÿâ ëå íèè ýëåê òðî ôî ðå çîì â àãà ðîç íîì ãåëå. Ðå çóëü òà òû. Äëÿ
íî ñè òå ëåé ìè íîð íî ãî àë ëå ëÿ (T/C + C/C) õà ðàê òåð íû áî ëåå âû ñî -
êèå ïî êà çà òå ëè îá ùå ãî õî ëåñ òå ðî ëà (5,4 ± 0,19 ïðî òèâ 4,8 ±
± 0,15 ììîëü/ë, P = 0,025) è õî ëåñ òå ðî ëà ëè ïîï ðî òå è íîâ íèç êîé
ïëîò íîñ òè (3,6 ± 0,17 ïðî òèâ 3,0 ± 0,14 ììîëü/ë, P = 0,008), à
òàê æå áî ëåå íèç êèé óðî âåíü õî ëåñ òå ðî ëà ëè ïîï ðî òå è íîâ âû ñî -
êîé ïëîò íîñ òè â ïëàç ìå êðî âè, ÷åì ó ãî ìî çè ãîò ïî îñíîâ íî ìó àë -
ëå ëþ (T/T). Âû âî äû. Íå óñòà íîâ ëå íî ñâÿ çè ìåæ äó ïî ëè ìîð ôèç-
ìîì T-138C ãåíà MGP è èç âåñ òíû ìè ôàê òî ðà ìè ðèñ êà àòå ðî-
ñêëå ðî çà è åãî îñëîæ íå íèé (èí äåê ñîì ìàñ ñû òåëà, ãè ïåð òåí çè åé,
ñà õàð íûì äè à áå òîì, êó ðå íè åì, ïî âû øåí íîé êî à ãó ëÿ öè îí íîé ñïî -
ñîá íîñ òüþ êðî âè) ó áîëü íûõ ñ èøå ìè ÷åñ êèì èí ñóëü òîì èç ñå âå ðî- 
âîñ òî÷ íî ãî ðå ãè î íà Óêðà è íû. Ó ïà öè åí òîâ – íî ñè òå ëåé ìè íîð íî -
ãî àë ëå ëÿ – çà ðå ãèñ òðè ðî âà íû áî ëåå âû ðà æåí íûå èç ìå íå íèÿ ëè -
ïîï ðî òå è íîâ ïëàç ìû êðî âè àòå ðî ãåí íî ãî õà ðàê òå ðà ïî ñðàâ íå-
íèþ ñ ãî ìî çè ãî òà ìè ïî îñíîâ íî ìó àë ëå ëþ.
Êëþ ÷å âûå ñëî âà: êàëü öè ôè êà öèÿ àð òå ðèé, èøå ìè ÷åñ êèé èí-
ñóëüò, ìàò ðèê ñíûé Gla-ïðî òå èí, ïî ëè ìîð ôèçì îäè íî÷ íûõ íóê ëåî- 
òè äîâ.
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